To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20140378469
    Abstract: LKB1 mutation status and/or expression, YES expression and phosphorylation level; and/or CD24 expression are employed to predict melanoma prognosis and response to therapeutics. Inhibitors (including targeted inhibitors) of SRC family kinases (especially YES) are employed to treat melanoma.
    Type: Application
    Filed: February 6, 2013
    Publication date: December 25, 2014
    Inventors: Norman Edward Sharpless, Wenjin Liu, James Bear, Kimberly Monahan, Kwok-Kin Wong
  • Publication number: 20140377777
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.
    Type: Application
    Filed: December 7, 2012
    Publication date: December 25, 2014
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Publication number: 20140377773
    Abstract: The present invention relates to specific markers capable of detecting the development of colorectal cancer and the colorectal cancer inhibitory effect of SeMet (selenomethionine) having a chemopreventive effect against colorectal cancer. When the expressions of the biomarkers according to the present invention are measured and the expression levels thereof are analyzed in combination, whether SeMet (selenomethionine) is to be administered to prevent colorectal cancer can be determined and the development of colorectal cancer and the inhibitory effect of SeMet (selenomethionine) against the development of colorectal cancer can be monitored. Thus, these markers can be effectively used to observe the colorectal cancer inhibitory effect of SeMet (selenomethionine) and the prognosis of colorectal cancer resulting from the intake of SeMet (selenomethionine).
    Type: Application
    Filed: July 30, 2013
    Publication date: December 25, 2014
    Applicant: Dongguk University Industry-Academic Cooperation Foundation
    Inventors: Young-Rok Seo, Md. Mujibur Rahman, Jong-Il Weon, Ju Han Lee, Jee Young Kwon, Hye Lim Kim
  • Publication number: 20140378470
    Abstract: This invention relates to methods of treating cancer in a subject such as a human and determining at least one of the following in a sample from the subject, such as a human: (a) the presence or absence of a mutation at the alanine 677 (A677) residue in EZH2; or (b) the presence or absence of a mutation at the tyrosine 641 (Y641) residue in EZH2; or (c) the presence or absence of an increased level of H3K27me3 as compared to a control, and administering to said human an effective amount of an EZH2 inhibitor or a pharmaceutically acceptable salt thereof if at least one of the A677 mutation, Y641 mutation, or increased level of H3K27me3 is present in the sample.
    Type: Application
    Filed: September 30, 2012
    Publication date: December 25, 2014
    Inventors: Caretha L. Creasy, Gopinath Ganji, Michael T. McCabe, Kimberly N. Smitheman
  • Publication number: 20140378528
    Abstract: This invention is based in part on the discovery that miR-34 is independent of p53. It has been discovered that miR-34 functions in a TP53-independent tumor suppression pathway. Specifically, miR-34-induced inhibition of cancer cell growth was found to be the same in p53-normal and p53-deficient cells. Thus, miR-34 has a more central role during tumor suppression that is uncoupled from p53. In the absence of p53, miR-34, unlike certain other miRNAs, is sufficient to induce an up-regulation of genes known to be regulated by p53, including but not limited to p21CIP1/WAF1 (CDKN1A), PUMA, BAX, NOXA, PHLDA3, and MDM2 and a down-regulation of HDAC1. Therefore, these biomarkers can be used as biomarkers of miR-34 activity. The invention is further based on the discovery that some of these biomarkers are indispensable for a therapeutic response to miR-34 activity, and are thus prerequisite biomarkers of miR-34 activity.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 25, 2014
    Inventors: Andreas Bader, Jane Zhao
  • Publication number: 20140370520
    Abstract: The invention relates to a method for diagnosing cancer, particularly bladder or prostate cancer using compounds of general formula (I): wherein R1, R2, R3, R4, R5 X, Y and z are as defined herein.
    Type: Application
    Filed: December 8, 2011
    Publication date: December 18, 2014
    Applicant: University College Cardiff Constultants Limited
    Inventors: Ian Weeks, Mohammad Jaffar, Richard Knox
  • Publication number: 20140370521
    Abstract: This invention provides novel biomarkers for Niemann-Pick disease, type C (NPC). In an exemplary embodiment, the invention provides methods for identifying a subject as having NPC. In embodiments, the methods involve detecting the level of biomarker selected from the group comprising i) galectin-3 (LGALS3); ii) cathepsin D (CTSD); iii) LGALS3 and CTSD; and iv) LGALS3 and/or CTSD in combination at least one additional NPC associated biomarker in a sample obtained from the subject. In embodiments, the methods involve comparing the level of biomarker to a reference.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 18, 2014
    Inventors: Forbes D. Porter, III, Celine V. M. Cluzeau, Dawn E. Watkins-Chow, Christopher A. Wassif, William J. Pavan
  • Publication number: 20140371156
    Abstract: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting component, wherein said compound comprises a membrane-active form.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 18, 2014
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventors: Matthew R. Pincus, Josef Michl, Ehsan Sarafraz-Yazdi
  • Patent number: 8911960
    Abstract: A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: December 16, 2014
    Assignee: Case Western Reserve University
    Inventors: Mark Chance, Kenneth Cooke, Daniela Schlatzer
  • Publication number: 20140363449
    Abstract: The technology described herein is directed to methods, assays, and systems relating to determining the level of SAKT signaling activity in a sample obtained from a subject as well as methods relating to administering inhibitors and/or agonists of SAKT signaling.
    Type: Application
    Filed: February 20, 2013
    Publication date: December 11, 2014
    Inventors: David Scadden, Dongjun Lee
  • Publication number: 20140363416
    Abstract: A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated kinase-activated protein kinase 2 (MK2), or a combination thereof, in an effective amount to reduce blood glucose in a subject. In other embodiments, the method involves administering to the subject a specific activator to increase X-box binding protein 1 (XBP1) phosphorylation on Thr48 and Ser61 in an effective amount to reduce blood glucose in the subject. Methods of identifying agents for reducing blood glucose in a subject are also provided.
    Type: Application
    Filed: August 30, 2012
    Publication date: December 11, 2014
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Umut Ozcan, Jaemin Lee
  • Publication number: 20140364329
    Abstract: The invention generally relates to methods for identifying protein-protein interactions. In certain aspects, methods of the invention involve conducting a protein-fragment complementation assay on a sample to form a protein-protein complex between two proteins in the sample that only transiently interact under physiological conditions, separating the complexes from the sample, and analyzing a protein of the complex using a mass spectrometry technique.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Inventors: Weiguo Andy Tao, Changdeng Hu
  • Publication number: 20140360403
    Abstract: A method for producing organic-inorganic composite materials includes at least one biomineralising protein and/or polypeptide-encoding recombinant polynucleotide being introduced into at least one host cell, preferably from the class of slime moulds, and the expressed protein and/or polypeptide influencing the formation of inorganic particles in an extracellular matrix of the host cell.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Ingrid Weiss, Eva Weber, Magdalena Eder, Eduard Arzt, Andreas Simon Schneider
  • Patent number: 8906636
    Abstract: The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: December 9, 2014
    Assignee: Pfenex Inc.
    Inventors: Diane M. Retallack, Lawrence Chew
  • Publication number: 20140356882
    Abstract: Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.
    Type: Application
    Filed: January 2, 2014
    Publication date: December 4, 2014
    Applicant: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Li Yan
  • Publication number: 20140356377
    Abstract: The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by excessive bleeding, such as surgery, trauma and internal bleeding. The inhibitor of antithrombin III can e.g. a peptide, an aptamer or an antibody or antibody fragment that specifically binds to and inhibits antithrombin III.
    Type: Application
    Filed: February 24, 2012
    Publication date: December 4, 2014
    Applicant: UMC Utrecht Holding B.V.
    Inventors: Cornelis Erik Hack, Cafer Yildiz
  • Publication number: 20140356883
    Abstract: The invention relates to a method for evaluating kits for rapid diagnosis of malaria, in order to determine or to test the sensitivity and specificity thereof. To that end, the reactive strips of the diagnostic kits are exposed to different concentrations of the malaria parasite in a method that allows data on sensitivity and specificity indicated on the technical sheet of the kit to be ascertained.
    Type: Application
    Filed: November 25, 2011
    Publication date: December 4, 2014
    Applicant: INSTITUTO NACIONAL DE SALUD
    Inventor: Nancy Arrospide Velasco
  • Publication number: 20140357627
    Abstract: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
    Type: Application
    Filed: June 9, 2014
    Publication date: December 4, 2014
    Inventors: Scott A. MITCHELL, Kevin S. CURRIE, Peter A. BLOMGREN, Jeffrey E. KROPF, Seung H. LEE, Jianjun XU, Douglas G. STAFFORD, James P. HARDING, Antonio J.M. BARBOSA, Jr., Zhongdong ZHAO, David M. ARMISTEAD, Soumya MITRA
  • Publication number: 20140356344
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Applicant: BioAtla LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20140356379
    Abstract: The present disclosure relates to isolated antibodies against human SPLA2-V and uses thereof.
    Type: Application
    Filed: October 10, 2012
    Publication date: December 4, 2014
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • Publication number: 20140357659
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darin W. Davis
  • Publication number: 20140349956
    Abstract: The subject invention pertains to materials and methods for diagnosing and/or predicting pathologic infant conditions. A method of the invention comprises obtaining a biological sample from an infant and analyzing the sample to detect at least one protein biomarker of necrotizing enterocolitis (NEC), wherein a patient is diagnosed with NEC or determined to have a likelihood of developing NEC following detection of the biomarker. In another method of the invention, the likelihood of a patient developing NEC is determined. In certain embodiments, treatment is administered to the patient following diagnosis of NEC or determination that the patient has a likelihood of developing NEC.
    Type: Application
    Filed: January 16, 2013
    Publication date: November 27, 2014
    Inventor: Josef Neu
  • Publication number: 20140348844
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: November 27, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenze, Matthew Cox
  • Publication number: 20140349873
    Abstract: Methods are described for the production and use of fluorescence resonance energy transfer (FRET)-based competitive displacement aptamer assay formats. The assay schemes involve FRET in which the analyte (target) is quencher (Q)-labeled and previously bound by a fluorophore (F)-labeled aptamer such that when unlabeled analyte is added to the system and excited by specific wavelengths of light, the fluorescence intensity of the system changes in proportion to the amount of unlabeled analyte added. Alternatively, the aptamer can be Q-labeled and previously bound to an F-labeled analyte so that when unlabeled analyte enters the system, the fluorescence intensity also changes in proportion to the amount of unlabeled analyte.
    Type: Application
    Filed: June 3, 2014
    Publication date: November 27, 2014
    Inventors: John Bruno, Joseph Chanpong
  • Publication number: 20140348821
    Abstract: Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 27, 2014
    Applicant: NSABP Foundation, Inc.
    Inventors: Katherine Lea Pogue-Geile, Soonmyung Paik
  • Publication number: 20140348833
    Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.
    Type: Application
    Filed: March 6, 2014
    Publication date: November 27, 2014
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
  • Publication number: 20140348857
    Abstract: The present invention relates to methods for treating endoplasmic reticulum (ER) stress-related conditions (e.g., cancer, protein folding/misfolding disease, diabetes mellitus) and for identifying compounds for treating ER stress-related conditions in a subject (e.g., a human). The invention also provides methods for diagnosing an ER stress-related condition in a subject and kits for the treatment of same.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 27, 2014
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Paul Chang, Miri Jwa, Sejal Kamlesh Vyas
  • Publication number: 20140349309
    Abstract: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided.
    Type: Application
    Filed: February 4, 2014
    Publication date: November 27, 2014
    Applicant: GILEAD BIOLOGICS, INC.
    Inventors: Victoria SMITH, Scott OGG, Peter VAN VLASSELAER, Vivian E. BARRY, Derek MARSHALL, Alison Kay HOLZER, Hector RODRIGUEZ, Miho OYASU, Scott Alan MCCAULEY, Carlos Aurelio GARCIA, Donna Hiroko Tokuoka BIERMANN
  • Publication number: 20140350047
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: March 27, 2014
    Publication date: November 27, 2014
    Applicants: University of Utah Research Foundation, The United States Government, as represented by the Department of Veterans Affairs
    Inventor: Matthew A. Movsesian
  • Publication number: 20140349278
    Abstract: A device and method for detecting and assessing the quantity of a biological, biochemical, or chemical analyte in a test sample using a simple light source and the naked eye are disclosed. In one embodiment, the device comprises a nanohole sensor chip with two sections, the first of which is a test section, upon which capture agents for a particular analyte are immobilized, and the second of which is a reference section, upon which capture agents conjugated with known quantities of the analyte are immobilized. In another embodiment of the invention, a nanohole sensor chip with a test section and a plurality of reference sections is disclosed. The sensor utilizes light intensity changes exhibited by Fano resonances in the nanoholes for detection of analytes, and allows comparison between the light intensity changes between the reference sections and the test sections for assessing the quantity of the analyte in the sample.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 27, 2014
    Applicant: KONICA MINOLTA LABORATORY U.S.A., INC.
    Inventor: Noriaki Yamamoto
  • Publication number: 20140349279
    Abstract: The present invention relates to a three dimensional (or 3D) microfluidic system comprising a plurality of layers stacked upon each other, characterised in that at least one of said layers consists of a 1st and at least one 2nd parts, distinct from each other, with the 2nd part being porous and wettable by a solution of interest, nesting into a recess of the 1st part being non-porous and/or non-wettable by said solution of interest, wherein said system can possibly have a built-in reservoir; a method for manufacturing the same and different uses thereof.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 27, 2014
    Inventors: Thomas Berthelot, Hervé Volland
  • Publication number: 20140348822
    Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.
    Type: Application
    Filed: June 10, 2014
    Publication date: November 27, 2014
    Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
  • Publication number: 20140349310
    Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.
    Type: Application
    Filed: September 13, 2012
    Publication date: November 27, 2014
    Applicant: Eli Lilly and Company
    Inventors: Julian Davies, Ling Liu, Jirong Lu
  • Publication number: 20140341927
    Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 20, 2014
    Applicant: Universite Laval
    Inventors: Jean-Pierre Julien, Makoto Urushitani
  • Publication number: 20140342373
    Abstract: The present invention concerns a microfluidic system comprising: a microchannel containing several elements of two non-miscible fluids, the microchannel comprising a droplet (30) containing magnetic particles (M), and a device for generating inside the microchannel magnetic field, said device comprising an activable magnetic element, the activable magnetic element comprising a tip (5,6), the microfluidic system being configured to transport the droplet by flow or by pressure difference.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 20, 2014
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Louis Viovy, Laurent Malaquin, Stefano Begolo, AnaïS Ali Cherif, Stephanie Descroix
  • Publication number: 20140336236
    Abstract: Novel ALK and NTRK1 fusion molecules and uses are disclosed.
    Type: Application
    Filed: April 21, 2014
    Publication date: November 13, 2014
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Doron Lipson, Roman Yelensky
  • Publication number: 20140335538
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.
    Type: Application
    Filed: July 31, 2014
    Publication date: November 13, 2014
    Inventor: Neil Cashman
  • Publication number: 20140336073
    Abstract: A method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 13, 2014
    Applicants: PALACKY UNIVERSITY, OLOMOUC, INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS ASCR, V.V.I.
    Inventors: Madhusudhan Reddy Kollaredy, Marian Hajduch, Petr Dzubak, Josef Srovnal, Rita Hrabakova, Hana Kovarova
  • Publication number: 20140335537
    Abstract: Apparatuses are disclosed for performing calorimetric assays with plucked human hair using a device adapted for that purpose. This device may include a transparent reaction vessel connected via a capillary tube to a burst pack, and connected via another capillary tube to a funnel, into which a plucked human hair may be placed.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 13, 2014
    Applicant: Follea International Ltd.
    Inventors: Andy Ofer Goren, John McCoy, Daniel Hafid
  • Publication number: 20140336070
    Abstract: The invention relates to improved electrochemiluminescence assay methods for phosphorylated peptides or proteins employing phospho-specific antibodies and buffer compositions that are substantially free of inorganic phosphate.
    Type: Application
    Filed: June 30, 2014
    Publication date: November 13, 2014
    Inventors: Michael Tsionsky, Eli N. Glezer, Selen Stromgren, George Sigal, Jonathan K. Leland, Mark A. Billadeau, Svetlana Leytner, Mark Martin, Larry Helms
  • Patent number: 8883144
    Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: November 11, 2014
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Edward C. Dempsey
  • Publication number: 20140329701
    Abstract: The invention relates to methods for deciding on the therapy in a subject suffering from colorectal cancer as well as for predicting the clinical outcome of a patient which suffers from colorectal cancer based on the expression level of KIAA1456 comprising determining the expression level of the KIAA1456 gene. The invention relates as well to kits and uses thereof comprising reagents adequate for the determination of the expression level of the KIAA1456 gene.
    Type: Application
    Filed: May 11, 2012
    Publication date: November 6, 2014
    Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
    Inventor: Fátima Valdés Mora
  • Publication number: 20140329252
    Abstract: A method of determining whether a subject is at risk of developing osteoarthritis (OA), said method comprising: determining the cellular localization of a Prohibitin-1 (PHB1) polypeptide and/or Small Ubiquitin-like Modifier (SUMO) polypeptide and/or UBC9, in a cell sample from said subject; and determining whether said subject is at risk of developing OA based on the cellular localization of a PHB1 polypeptide and/or SUMO and/or UBC9 polypeptide, is described.
    Type: Application
    Filed: October 15, 2012
    Publication date: November 6, 2014
    Inventor: Alain Moreau
  • Publication number: 20140329787
    Abstract: The present invention relates to a novel Phytophthora phospholipase C and uses thereof, methods of identifying modulators and inhibitors of a biological function of the phospholipase C, and methods of inhibiting Phytophthora growth comprising inhibiting a biological function of a novel Phytophthora phospholipase C.
    Type: Application
    Filed: October 17, 2012
    Publication date: November 6, 2014
    Inventors: Dean Ian Phillips, Peter Luke Beech
  • Publication number: 20140329253
    Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.
    Type: Application
    Filed: November 26, 2012
    Publication date: November 6, 2014
    Applicant: Fraunhofer-Gesllschaft zur Foerderung der angewandten Forschung e.V.
    Inventors: Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
  • Publication number: 20140329706
    Abstract: Affinity tags and ligands comprising a PDZ domain peptide and a PDZ binding carboxy terminal peptide and related engineered protein, engineered labels, compositions, methods and systems.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventor: Ward Gale WALKUP, IV
  • Publication number: 20140322703
    Abstract: A method for the quantitative determination of an analyte in a sample is provided comprising: (a) providing an analyte-specific substance which is able to undergo a reaction which generates a detectable signal when it is contacted with an analyte; (b) providing at least two calibration graphs which have been generated by reacting in each case the same analyte-specific substance with different amounts of in each case the same test analyte for in each case a predetermined reaction time; (c) contacting the analyte-specific substance with a sample which contains the analyte to be detected; (d) measuring the signal at a first predetermined reaction time for which a first calibration graph according to (b) is provided; (c) checking whether the signal measured according to (d) enables a quantitative determination of the analyte with a desired accuracy; (f) (i) quantitatively determining the analyte on the basis of the signal measured according to (d) if the desired accuracy is reached, or (ii) measuring the signal a
    Type: Application
    Filed: July 14, 2014
    Publication date: October 30, 2014
    Inventors: Jürgen Spinke, Marcel Thiele, Jürgen Schäffler, Andreas Nufer
  • Publication number: 20140323551
    Abstract: The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 30, 2014
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Leland W.K. Chung, Sajni Josson, Murali Gururajan, Anjali Jain
  • Publication number: 20140323346
    Abstract: The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Applicant: Garvan Institute of Medical Research
    Inventors: Roger John Daly, Ian Peter Holmes, Ian Street, Scott Raymond Walker
  • Publication number: 20140323339
    Abstract: Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS.
    Type: Application
    Filed: July 10, 2014
    Publication date: October 30, 2014
    Applicant: FLUIDIGM CANADA INC.
    Inventor: Olga Ornatsky